New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
07:13 EDTSRPTSarepta to host conference call
Management discusses plans to submit to the FDA, a New Drug Application by year end 2014, for Eteplirsen for treatment of Duchenne Muscular Dystrophy on a conference call to be held on April 21 at 8 am. Webcast Link
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
11:19 EDTSRPTSarepta climbs after analyst says FDA poised to accept drug application
Subscribe for More Information
10:03 EDTSRPTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTSRPTOn The Fly: Pre-market Movers
Subscribe for More Information
07:11 EDTSRPTSarepta upgraded to Outperform from Neutral at Baird
As previously reported, Baird upgraded Sarepta to Outperform from Neutral and increased its price target to $20 from $16. The firm said last night's NDA submission by potential competitor BioMarin (BMRN) indicates the FDA will review both applications and expects Sarepta to solidify a mid-2015 submission following a Q2 meeting with the agency. Baird believes shares could trade above $20 once the NDA is accepted, versus downside of $6-$7 on a significant delay.
06:55 EDTSRPTSarepta upgraded to Outperform from Neutral at Baird
May 5, 2015
15:46 EDTSRPTRick Barry accepts nomination to join Sarepta board
Rick Barry disclosed a 7.66% stake in Sarepta Therapeutics and noted he has been nominated to join the board of the company and has accepted the nomination. No additional purchase or disposition of securities occurred since the last filing of Schedule 13G on February 19, the current filing noted.
May 1, 2015
16:19 EDTSRPTPoint72 Asset reports 5.3% passive stake in Sarepta
07:06 EDTSRPTSarepta announces inducement grants under Nasdaq listing rule 5635(c)(4)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use